These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
280 related articles for article (PubMed ID: 19735356)
1. 2009 update on phosphodiesterase type 5 inhibitor therapy part 2: updates on optimal utilization for sexual concerns and rare toxicities in this class. Shindel AW J Sex Med; 2009 Sep; 6(9):2352-64; quiz 2365-6. PubMed ID: 19735356 [TBL] [Abstract][Full Text] [Related]
2. 2009 update on phosphodiesterase type 5 inhibitor therapy part 1: Recent studies on routine dosing for penile rehabilitation, lower urinary tract symptoms, and other indications (CME). Shindel AW J Sex Med; 2009 Jul; 6(7):1794-808; quiz 1793, 1809-10. PubMed ID: 19575771 [TBL] [Abstract][Full Text] [Related]
3. Treating erectile dysfunction and central neurological diseases with oral phosphodiesterase type 5 inhibitors. Review of the literature. Lombardi G; Nelli F; Celso M; Mencarini M; Del Popolo G J Sex Med; 2012 Apr; 9(4):970-85. PubMed ID: 22304626 [TBL] [Abstract][Full Text] [Related]
4. The ENDOTRIAL study: a spontaneous, open-label, randomized, multicenter, crossover study on the efficacy of sildenafil, tadalafil, and vardenafil in the treatment of erectile dysfunction. Jannini EA; Isidori AM; Gravina GL; Aversa A; Balercia G; Bocchio M; Boscaro M; Carani C; Corona G; Fabbri A; Foresta C; Forti G; Francavilla S; Granata AR; Maggi M; Mansani R; Palego P; Spera G; Vetri M; Lenzi A; J Sex Med; 2009 Sep; 6(9):2547-60. PubMed ID: 19570039 [TBL] [Abstract][Full Text] [Related]
5. Phosphodiesterase type 5 inhibitors and female sexual response: faulty protocols or paradigms? Chivers ML; Rosen RC J Sex Med; 2010 Feb; 7(2 Pt 2):858-72. PubMed ID: 19929916 [TBL] [Abstract][Full Text] [Related]
6. Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction. Mulhall JP; McLaughlin TP; Harnett JP; Scott B; Burhani S; Russell D J Sex Med; 2005 Nov; 2(6):848-55. PubMed ID: 16422809 [TBL] [Abstract][Full Text] [Related]
7. Erectile dysfunction diagnosis and treatment as a means to improve medication adherence and optimize comorbidity management. Scranton RE; Goldstein I; Stecher VJ J Sex Med; 2013 Feb; 10(2):551-61. PubMed ID: 23153075 [TBL] [Abstract][Full Text] [Related]
8. Failure of PDE5 inhibitor use: a case of nonresponder? (CME). Chung E J Sex Med; 2010 Apr; 7(4 Pt 1):1321-3. PubMed ID: 20492423 [No Abstract] [Full Text] [Related]
9. Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient. Corona G; Mondaini N; Ungar A; Razzoli E; Rossi A; Fusco F J Sex Med; 2011 Dec; 8(12):3418-32. PubMed ID: 21995676 [TBL] [Abstract][Full Text] [Related]
10. Phosphodiesterase 5 inhibitors for erectile dysfunction. Setter SM; Iltz JL; Fincham JE; Campbell RK; Baker DE Ann Pharmacother; 2005; 39(7-8):1286-95. PubMed ID: 15941818 [TBL] [Abstract][Full Text] [Related]
11. 10-Year analysis of adverse event reports to the Food and Drug Administration for phosphodiesterase type-5 inhibitors. Lowe G; Costabile RA J Sex Med; 2012 Jan; 9(1):265-70. PubMed ID: 22023666 [TBL] [Abstract][Full Text] [Related]
12. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability. Wang R; Burnett AL; Heller WH; Omori K; Kotera J; Kikkawa K; Yee S; Day WW; DiDonato K; Peterson CA J Sex Med; 2012 Aug; 9(8):2122-9. PubMed ID: 22759639 [TBL] [Abstract][Full Text] [Related]
13. A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient? Hatzimouratidis K; Hatzichristou DG Drugs; 2005; 65(12):1621-50. PubMed ID: 16060698 [TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy of tadalafil once daily in men with erectile dysfunction who demonstrated previous partial responses to as-needed sildenafil, tadalafil, or vardenafil. Kim E; Seftel A; Goldfischer E; Baygani S; Burns P Curr Med Res Opin; 2015 Feb; 31(2):379-89. PubMed ID: 25455432 [TBL] [Abstract][Full Text] [Related]
15. Timing of dose relative to sexual intercourse attempt in previous sildenafil citrate users treated with tadalafil: a geographical comparison from a single arm, open-label study. Rubio-Aurioles E; Glina S; Abdo CH; Hernandez-Serrano R; Rampazzo C; Sotomayor M; West TM; Gallagher GL; Lenero E J Sex Med; 2009 Oct; 6(10):2836-50. PubMed ID: 19674256 [TBL] [Abstract][Full Text] [Related]
16. The Global Online Sexuality Survey (GOSS): the United States of America in 2011 chapter II: phosphodiesterase inhibitors utilization among English speakers. Shaeer O J Sex Med; 2013 Feb; 10(2):532-40. PubMed ID: 23088586 [TBL] [Abstract][Full Text] [Related]
18. Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study. Eardley I; Montorsi F; Jackson G; Mirone V; Chan ML; Loughney K; Vail GM; Beardsworth A BJU Int; 2007 Jul; 100(1):122-9. PubMed ID: 17552960 [TBL] [Abstract][Full Text] [Related]
19. New phosphodiesterase inhibitors in the treatment of erectile dysfunction. Anderson PC; Gommersall L; Hayne D; Arya M; Patel HR Expert Opin Pharmacother; 2004 Nov; 5(11):2241-9. PubMed ID: 15500370 [TBL] [Abstract][Full Text] [Related]
20. Phosphodiesterase 5 inhibitors in male sexual dysfunction. Kuthe A Curr Opin Urol; 2003 Sep; 13(5):405-10. PubMed ID: 12917517 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]